[go: up one dir, main page]

UY31232A1 - Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones - Google Patents

Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Info

Publication number
UY31232A1
UY31232A1 UY31232A UY31232A UY31232A1 UY 31232 A1 UY31232 A1 UY 31232A1 UY 31232 A UY31232 A UY 31232A UY 31232 A UY31232 A UY 31232A UY 31232 A1 UY31232 A1 UY 31232A1
Authority
UY
Uruguay
Prior art keywords
group
dibenzotifenilamino
cromen
isomers
replaced
Prior art date
Application number
UY31232A
Other languages
English (en)
Inventor
Niall Morrison Barr Martin
Sylvie Gomez
Heather Mary Ellen Duggan
Christine Sarah Bailey
Marc Geoffrey Hummersone
Keith Allan Menear
Frigerio Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31232A1 publication Critical patent/UY31232A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuestos de la formula I, en donde: R1 y R2 se seleccionan de manera independiente entre hidrogeno, un grupo alquilo C1-7, un grupo heterociclilo C3-20 o arilo C5-20 opcionalmente sustituido, o juntos pueden formar, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalemente sustituido que tiene entre 4 y 8 átomos de anillo; X es CH o N; n es 1 o 2; RC1 y Rc2 se seleccionan de manera independiente entre H y metilo; cuando X es N, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido y sulfonilo; y cuando X es CH, Rx se selecciona del grupo que consiste de H, y un grupo opcionalmente sustituido de alquilo C1-7, heterociclilo C3-20, arilo C5-20, acilo, éster, amido, sulfonilo, amino y éter.
UY31232A 2007-07-19 2008-07-17 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones UY31232A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95063107P 2007-07-19 2007-07-19
US3656008P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
UY31232A1 true UY31232A1 (es) 2009-03-02

Family

ID=39791057

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31232A UY31232A1 (es) 2007-07-19 2008-07-17 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Country Status (14)

Country Link
US (1) US20090042865A1 (es)
EP (1) EP2176254A1 (es)
JP (1) JP2010533694A (es)
KR (1) KR20100063701A (es)
CN (1) CN101754964A (es)
AR (1) AR067613A1 (es)
AU (1) AU2008277418A1 (es)
BR (1) BRPI0814797A2 (es)
CA (1) CA2693926A1 (es)
CL (1) CL2008002130A1 (es)
RU (1) RU2009149210A (es)
TW (1) TW200918528A (es)
UY (1) UY31232A1 (es)
WO (1) WO2009010761A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) * 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 rup3 또는 gpr119 수용체의 작용제로서 n-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011137428A1 (en) * 2010-04-30 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating hiv infection: inhibition of dna dependent protein kinase
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法
CN111053903A (zh) * 2019-12-26 2020-04-24 深圳市纳诺艾医疗科技有限公司 一种携带共振原子的核酸类似物的化合物的应用
TW202235074A (zh) * 2021-01-05 2022-09-16 大陸商山東軒竹醫藥科技有限公司 多環類激酶抑制劑
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
ATE203904T1 (de) * 1993-04-09 2001-08-15 Toyama Chemical Co Ltd Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
JP4103968B2 (ja) * 1996-09-18 2008-06-18 株式会社半導体エネルギー研究所 絶縁ゲイト型半導体装置
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
ATE461193T1 (de) * 2003-08-13 2010-04-15 Kudos Pharm Ltd Aminopyrone und ihre verwendung als atm inhibitoren
TW200616986A (en) * 2004-09-20 2006-06-01 Kudos Pharm Ltd DNA-pk inhibitors
JP2008529995A (ja) * 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Atm阻害剤
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
JP5781720B2 (ja) * 2008-12-15 2015-09-24 ルネサスエレクトロニクス株式会社 半導体装置及び半導体装置の製造方法

Also Published As

Publication number Publication date
US20090042865A1 (en) 2009-02-12
AU2008277418A1 (en) 2009-01-22
JP2010533694A (ja) 2010-10-28
CA2693926A1 (en) 2009-01-22
WO2009010761A1 (en) 2009-01-22
RU2009149210A (ru) 2011-08-27
CL2008002130A1 (es) 2009-01-02
TW200918528A (en) 2009-05-01
KR20100063701A (ko) 2010-06-11
AR067613A1 (es) 2009-10-14
EP2176254A1 (en) 2010-04-21
BRPI0814797A2 (pt) 2015-02-03
CN101754964A (zh) 2010-06-23

Similar Documents

Publication Publication Date Title
UY31232A1 (es) Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
PH12012501532A1 (en) Di-substituted pyridine derivatives as anticancers
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
JO2947B1 (en) Compounds corresponding to cyclopamine
UY31603A1 (es) Derivados de ftalazinona
NO20071873L (no) DNA-PK inhibotorer.
MY152972A (en) Azabicyclo compound and salt thereof
MX381623B (es) Composición limpiadora.
EA201171328A1 (ru) Производное замещенного изохинолина
MX2015007883A (es) Compuestos para protección de células.
ES2530398T3 (es) Pirrolidin-2-onas 4-sustituidas y su uso
DE602004026071D1 (de) Aminopyrone und ihre verwendung als atm inhibitoren
MX2010007593A (es) Derivados novedosos de acil cianopirrolidinas.
MX2016014239A (es) Composicion limpiadora.
CO6320143A1 (es) Nuevos derivados dihidroindolonas su procedimeinto de preparacion y composiciones farmaceuticas que los contienen
AR060379A1 (es) Compuesto y composicion herbicida
CY1117560T1 (el) Νεο υποκατασταθεν παραγωγο ισοκινολινης
TN2011000429A1 (en) Derivatives of benzothiazines, preparation thereof and application thereof as drugs
ATE528284T1 (de) Metallcarbamate aus tolylendiaminen
GB2470170A (en) Dithienothiophene derivatives
IN2012DN01251A (es)
CR20110306A (es) Derivados de morfina-6-glucuronido, su preparación y su aplicación en terapéutica
MX2009004075A (es) Derivados de alfa-, omega-aminoalcohol, enriquecidos en enantiomeros, su preparacion y uso como agentes repelentes de insectos y acaros.
ES2531049T3 (es) Preparado estabilizado de 3,3-dialcoxi-1-propeno

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171009